Tandem Diabetes Care (NSDQ:TNDM) shareholders met yesterday and approved a proposal to effect a reverse stock split at a ratio between 1-for-8 and 1-for-12, according to a regulatory document.
In a statement filed with the SEC in July, the San Diego, Calif.-based company told shareholders that it believed a reverse stock split would help Tandem keep its common stock listed on the Nasdaq market and make its stock more attractive to institutional investors.
“Our board of directors further believes that an increased stock price may also encourage investor interest and improve the marketability of our common stock to a broader range of investors, and thus improve the liquidity of our shares and lower average transaction costs for our stockholders,” the company wrote.
Get the full story at our sister site, Drug Delivery Business News.